» Articles » PMID: 989476

Bioavailability of Tolamolol

Overview
Specialty Pharmacology
Date 1976 Feb 6
PMID 989476
Authors
Affiliations
Soon will be listed here.
Abstract

Bioavailability of capsule and tablet formulations of tolamolol were compared by measuring plasma concentration of tolamolol and reduction in maximum exercise heart rate over a period of twelve hours in eight healthy subjects in a two-way cross-over study. Tolamolol was absorbed more rapidly from capsules than from tablets; this did not result in any significant difference in the reduction in maximum exercise heart rate between the two formulations. There was no significant difference between area under curve of reduction in exercise tachycardia and area under-curve of plasma concentration of tolamolol for the two formulations. Reduction in maximum exercise heart rate was related to logarithm of plasma concentration of tolamolol between two and twelve hours after both formulations.

References
1.
Rickham P . RESPONSIBILITY IN INVESTIGATIONS ON HUMAN SUBJECTS. STATEMENTS BY MEDICAL RESEARCH COUNCIL. Br Med J. 1964; 2(5402):178-9. PMC: 1816147. DOI: 10.1136/bmj.2.5402.178. View

2.
Ormrod R . Medical ethics. Br Med J. 2010; 2(5596):7-10. PMC: 1985570. DOI: 10.1136/bmj.2.5596.7. View

3.
Stopher D . Thin layer chromatography-fluorimetic estimation of tolamolol in human plasma. J Pharm Pharmacol. 1975; 27(2):133-4. DOI: 10.1111/j.2042-7158.1975.tb09423.x. View

4.
Taylor S, Thadani U, Davidson C, Singleton W, Myint S . A comparative study of the activity of beta-adrenoceptor antagonists in man. Int J Clin Pharmacol Biopharm. 1975; 12(1-2):305-6. View

5.
Augstein J, Cox D, Ham A, Leeming P, SNAREY M . Beta-adrenoceptor blocking agents. 1. Cardioselective 1-aryloxy-3-(aryloxyalkylamino)propan-2-ols. J Med Chem. 1973; 16(11):1245-51. DOI: 10.1021/jm00269a007. View